Background
Inflammation is now recognized as a major driver of atherosclerotic cardiovascular disease, not just cholesterol and blood pressure. One of the central molecular systems involved in this process is the NLRP3 inflammasome, a cellular “alarm system” that helps detect harmful signals from infection, tissue injury, metabolic stress, and other triggers. When overactivated, it can amplify inflammation and contribute to conditions such as obesity-related inflammation, insulin resistance, and atherosclerosis.
Ruvonoflast is an oral inhibitor of NLRP3 developed to reduce this inflammatory signaling. Earlier early-phase clinical observations suggested that it may lower biomarkers of systemic inflammation, including high-sensitivity C-reactive protein, or hsCRP, which is a widely used marker of residual inflammatory risk. Residual inflammatory risk refers to continued inflammatory activity despite standard cardiovascular prevention therapy.
Why this study mattered
Even when cholesterol is well controlled, some people remain at elevated risk of heart attack, stroke, and other cardiovascular events because inflammation persists. Researchers have been looking for therapies that directly reduce inflammation without causing unacceptable side effects. This study evaluated whether oral ruvonoflast could lower inflammatory biomarkers in people with high cardiovascular risk, obesity, and elevated hsCRP.
Study design
This was a double-blind Phase 1b randomized trial. Participants had hsCRP of at least 2.5 mg/L, body mass index between 30 and 40 kg/m2, and at least one additional cardiometabolic condition such as dyslipidemia, hypertension, or type 2 diabetes. A total of 63 participants were randomized to receive either oral ruvonoflast 225 mg twice daily (40 participants) or matching placebo (23 participants).
To reduce confounding from diet, both groups were maintained on a 2000 kcal/day diet throughout the study. The primary endpoint was the change in hsCRP at Day 28, expressed as a ratio to baseline. The main analysis used a Bayesian analysis of covariance, and the researchers also examined changes over time using a mixed-effects model with repeated measures. Secondary endpoints included changes in other inflammatory markers such as interleukin-6 (IL-6) and fibrinogen, as well as body weight.
Who participated
Among the 63 randomized participants, the mean age was 52.6 years. Most were women (71.4%), and most were white (69.8%). The median baseline hsCRP was 5.7 mg/L, with an interquartile range of 3.9 to 9.8 mg/L, confirming that the study population had substantial inflammatory burden at enrollment. Fifty-nine participants completed the study.
Main findings
The study met its primary endpoint. At Day 28, the posterior probability that ruvonoflast was superior to placebo for reducing hsCRP was greater than 99%. In practical terms, this means the data strongly favored the active drug over placebo.
The anti-inflammatory effect appeared early. Between-group differences favoring ruvonoflast were statistically significant from Day 3 onward, with p values of 0.001 or less. By Day 28, the geometric least-squares mean reduction in hsCRP was 82.2% in the ruvonoflast group, compared with 37.2% in the placebo group.
This is an important distinction: the placebo group also improved, likely reflecting the effects of the standardized diet, study participation, or natural variation in inflammation. However, the reduction with ruvonoflast was much greater.
When treatment stopped, hsCRP returned to baseline 7 days later, suggesting that the anti-inflammatory effect was pharmacologically driven and reversible rather than permanently altering the underlying inflammatory state.
Secondary biomarker results
Ruvonoflast also significantly lowered two key secondary inflammatory biomarkers: IL-6 and fibrinogen. Both are relevant to cardiovascular risk. IL-6 is a signaling molecule involved in inflammatory cascades, and fibrinogen is linked to both inflammation and clot formation. Reductions in these markers support the conclusion that ruvonoflast was broadly suppressing inflammatory activity, not only affecting hsCRP.
Body weight and metabolic effects
Both treatment groups experienced similar mean percentage reductions in body weight by Day 28. This suggests that the major difference between groups was not weight loss itself, but the anti-inflammatory action of ruvonoflast. Because obesity and inflammation are closely linked, it is notable that the biomarker improvements occurred alongside similar weight change in both arms.
Safety and tolerability
Overall safety was acceptable in this short study, but adverse events did occur. Serious treatment-emergent adverse events were similar between groups. However, four participants in the ruvonoflast group, representing 10%, discontinued treatment because of transient and reversible treatment-emergent adverse events, while no participants in the placebo group discontinued for this reason.
This means the drug showed clear biologic activity, but tolerability will need close monitoring in larger and longer trials. Phase 1b studies are designed primarily to assess early safety signals and biological effect, so these findings are informative but not definitive.
Clinical interpretation
The most important message from this trial is that oral inhibition of NLRP3 with ruvonoflast produced a rapid and substantial reduction in hsCRP, along with improvements in other inflammatory biomarkers, in people with high inflammatory and cardiovascular risk.
This supports the broader idea that targeting innate immune pathways may become an effective strategy for preventing atherosclerotic events in selected patients. At present, standard care for cardiovascular risk reduction still includes lipid-lowering therapy, blood pressure control, diabetes management, smoking cessation, healthy diet, physical activity, and weight management. Anti-inflammatory therapy may eventually add another layer of protection for patients whose inflammatory risk remains high despite these measures.
Limitations
Because this was a relatively small Phase 1b study, several limitations should be kept in mind. The sample size was modest, the treatment period was short, and the study was not designed to determine whether ruvonoflast prevents heart attacks, strokes, or cardiovascular death. Biomarker improvement is encouraging, but it does not automatically guarantee clinical benefit.
In addition, the population was selected for obesity and elevated hsCRP, so the results may not apply to all patients with cardiovascular disease. Longer studies will be needed to determine durability of effect, long-term safety, dose optimization, and whether biomarker reductions translate into fewer major cardiovascular events.
Conclusion
In this randomized double-blind study, oral ruvonoflast significantly reduced hsCRP and lowered additional inflammatory biomarkers in participants with elevated cardiovascular and inflammatory risk. The findings provide early proof of concept that NLRP3 inhibition may be a promising anti-inflammatory strategy.
Ongoing Phase 2 trials, which are larger and longer in duration, will be essential to clarify whether this approach can safely deliver meaningful cardiovascular benefit in real-world practice.
